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Surgical Outcomes in Small Cell Lung Cancer
Min  Ho  Ju,  M.D.,  Hyeong  Ryul  Kim,  M.D.,  Joon-Bum  Kim,  M.D.,  Yong  Hee  Kim,  M.D., 
Dong  Kwan  Kim,  M.D.,  Seung-Il  Park,  M.D.
Background:  The experience of a single-institution regarding surgery for small cell lung cancer (SCLC) was re-
viewed to evaluate the surgical outcomes and prognoses. Materials and Methods: From July 1990 to December 
2009, thirty-four patients (28 male) underwent major pulmonary resection and lymph node dissection for SCLC. 
Lobectomy was performed in 24 patients, pneumonectomy in eight, bilobectomy in one, and segmentectomy in one. 
Surgical complications, mortality, the disease-free survival (DFS) rate, and the overall survival rate were analyzed 
retrospectively.  Results: The median follow-up period was 26 months (range, 4 to 241 months), and there was 
one surgical mortality (2.9%). Six patients (17.6%) experienced recurrence, all of which were systemic. Eight pa-
tients died during follow-up; four died of disease progression and the other four died of pneumonia or of another 
non-cancerous cause. The three-year DFS rate was 79.2±2.6% and the overall survival rate was 66.4±10.5%. 
Recurrence or death was significantly prevalent in the patients with lymph node metastasis (p=0.001) as well as in 
those who did not undergo adjuvant chemotherapy (p=0.008). The three-year survival rate was significantly greater 
in the patients with pathologic stage I/II cancer than in those with stage III cancer (84% vs. 13%, p=0.001). 
Conclusion: Major pulmonary resection for small cell lung cancer is feasible in selected patients. Patients with 
pathologic stage I or II disease showed an excellent survival rate after surgery and adjuvant treatment. Prospective 
randomized studies will be needed to define the role of surgery in early-stage small cell lung cancer.
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INTRODUCTION
Small  cell  lung  cancer  (SCLC)  has  a  poor  prognosis  be-
cause  of  its  rapid  growth  rate  and  early  metastatic  dissem-
ination  [1,2].  In  general,  systemic  chemotherapy,  with  or 
without  radiotherapy,  has  been  recommended  as  the  appro-
priate  therapy,  and  surgery  has  had  only  a  limited  role  [3]. 
Pulmonary  resection  has  been  used  as  part  of  a  combination 
therapy [4,5] or for residual lesions following concurrent che-
moradiotherapy  (CCRT).  Pulmonary  resection  has  also  been 
used  for  mixed  type  lesions  with  non-small  cell  lung  cancer 
(NSCLC). There have only been a few reports regarding sur-
gical  outcomes  in  patients  with  SCLC  [6-9].  Surgery  does 
have  an  established  role  for  treating  SCLC.  We  investigated 
the  outcomes  and  risk factors  of  surgery  in  the  patients  from 
a single institution who underwent major pulmonary resection 
for  SCLC  within  the  past  20  years.Surgical Outcome in Small Cell Lung Cancer
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Table 1. Patient characteristics (n=34)
Variables Values
Gender  (male)
Age  (yr)
Follow-up  period  (mo)
Clinical  stage
  I
  I I
    III
  I V
Pathological  stage
  I
  I I
    III
  I V
  U p s t a g i n g
  D o w n s t a g i n g
Surgical  extent
    Lobectomy
    Pneumonectomy
    Segmentectomy
  B i l o b e c t o m y
    Concomitant  resection*
Cell  type
  P u r e  S C L C
    Mixed  type
    S q u a m o u s  c e l l  c a r c i n o m a
    A d e n o c a r c i n o m a
        Large  cell  carcinoma
    O t h e r
28  (82.4)
61.7±8.8
 5 3 . 4 ±63.8
21  (61.8)
  9  (26.5)
  4  (11.8)
0  (0)
10  (29.4)
16  (47.1)
  8  (23.5)
0  (0)
13  (38.2)
  4  (11.8)
   
24  (70.6)
  8  (23.5)
1  (2.9)
1  (2.9)
3  (8.8)
24  (70.6)
10  (29.4)
  4  (11.8)
3  (8.8)
2  (5.9)
1  (2.9)
Values  are  presented  as  mean±standard  deviation  or  number  (%).
SCLC=small  cell  lung  cancer.
*Major  pulmonary  resection  with  surrounding  tissues,  i.e.,  chest 
wall,  rib,  pericardium,  diaphragm,  etc.
MATERIALS AND METHODS
A  total  of  3,194  patients  underwent  major  pulmonary  re-
section  for  malignant  neoplasm  at  our  institution  from  April 
1990  to  December  2009.  A  pathology  review  confirmed 
SCLC  in  34  of  these  patients  (0.01%).  The  pulmonary  re-
sections  were  performed  via  a  posterolateral  thoracotomy 
(n=31) or video-assisted thoracoscopic surgery (VATS) (n=3). 
Mediastinal lymph node dissections were routinely performed, 
and  all  patients  who  had  any  component  of  SCLC  seen  on 
histology were included in this study. The Kaplan-Meier anal-
ysis  was  used  to  plot  the  survival  curves  and  the  rates  of 
freedom  from  recurrence  as  well  as  to  compare  the  survival 
rates between stage I and II, and stage III disease. Univariate 
Cox  regression  analyses  were  used  for  risk  factor  analysis  of 
death  or disease  recurrence.  Statistical  analyses  were  performed 
using SPSS ver. 16.0 (SPSS Inc., Chicago, IL, USA). Statistical 
significance  was  defined  as  a  2-sided  p-value  ≤0.05.  This 
study  was  conducted  using  a  retrospective  chart  review.  The 
seventh  edition  of  the  American  Joint  Committee  on  Cancer 
(AJCC)  Cancer  Staging  was  used  for  the  stage  classification.
RESULTS
1) Patient characteristics
A total of 34 patients with SCLC underwent major pulmo-
nary resection. There were 28 males (82.4%) and six females 
( 1 7 . 6 % ) ,  a n d  t h e  m e a n  a g e  w a s  6 4  y e a r s  ( r a n g e ,  4 4  t o  7 6  
years).  Three  patients  underwent  neoadjuvant  chemotherapy. 
Lobectomy  was  performed  in  24  patients  (70.6%),  and  pneu-
monectomy  was  performed  in  8  patients  (23.5%).  A  segmen-
tectomy  and  bilobectomy  were both  performed  in  one  patient 
(2.9%)  (Table  1).  Mediastinoscopic  lymph  node  dissection 
followed  by  lobectomy  using  VATS  was  performed  on  three 
patients. The other thirty-one patients underwent posterolateral 
thoracotomy.
2) Surgical outcomes
There  was  one  case  of  surgical  mortality  (2.9%).  This  pa-
tient  died  of  sudden  cardiac  arrest,  and  the  cause  of  shock 
was thought to be bleeding at the pneumonectomy site. There 
were no major postoperative complications in any of the oth-
er  cases.
Pure  SCLC  was  confirmed  in  24  patients  (70.6%),  and 
mixed  type  tumors  with  NSCLC  was  confirmed  in  10  pa-
tients  (29.4%)  on  the  postoperative  histological  examination. 
Squamous cell lung cancer was most often accompanied by a 
mixed histology (n=4, 11.8%). Twenty-six patients had patho-
logic  stage  I  or  II  disease,  and  eight  patients  had  stage  III 
disease  (Table  1).
Thirty patients (88.2%) received adjuvant therapy. Nineteen 
patients  (55.9%)  received  only  radio-therapy.  Ten  patients 
(29.4%) received CCRT, and one patient (2.9%) received on-
ly  chemotherapy.  Adjuvant  therapy  was  not  performed  in 
three  patients  because  of  either  their  poor  general  condition Min Ho Ju, et al
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Table 2. Treatment combined with surgical resection in patients 
with small cell lung cancer 
Variables Values
Neoadjuvant  therapy
Adjuvant  therapy
    Radiotherapy  only
    Chemotherapy+radiotherapy
    Chemotherapy  only
None
 3  ( 8 . 8 )
  30  (88.2)
  19  (55.9)
  10  (29.4)
 1  ( 2 . 9 )
 3  ( 8 . 8 )
V a l u e s  a r e  p r e s e n t e d  a s  n u m b e r  ( % ) .
Table 3. Surgical outcomes for patients with small cell lung can-
cer
Variables Values
Recurrence
    Local
  S y s t e m i c
Death
    Operative  mortality
    Disease  progression
    Pneumonia  or  sepsis
    Pulmonary  thromboembolism
  O t h e r
  6  (17.6)
0  (0)
    6  (100.0)
  9  (26.5)
1  (2.9)
  4  (11.8)
2  (5.8)
1  (2.9)
1  (2.9)
V a l u e s  a r e  p r e s e n t e d  a s  n u m b e r  ( % ) .
Fig. 1. Overall survival rate determined using the Kaplan-Meier 
method. The overall survival rate was 66.4±10.5% at five years 
after surgery.
Fig. 2. Freedom from recurrence rate after surgical resection, de-
termined using the Kaplan-Meier method. The freedom from re-
currence rate was 79.2±2.6% at five years after surgery.
or  other  complications  (Table  2).
The  median  follow-up  period  was  26  months  (range,  4  to 
241 months). There were eight late deaths (26.5%) during the 
follow-up  period;  four  died  of  disease  progression  and  the 
other four died of pneumonia or another non-cancerous cause. 
The cancer recurred in six cases (17.6%), which were all sys-
temic  recurrences  (Table  3).
In this study, the overall five-year survival rate was 66.4% 
(Fig.  1)  and  the  three-year  disease-free  survival  rate  was 
79.2%  (Fig.  2).  The  three-year  survival  rate  according  to  the 
pathologic stage was 84% in patients with stage I and II dis-
ease  and  13%  in  patients  with  stage  III  disease  (p=0.001) 
(Fig.  3).
3) Risk factors for death or recurrence
The  risk  factors  for  death  or  disease  recurrence  were  ana-
lyzed  using  the  univariate  Cox-regression  hazard  model.  As 
the number of the deaths and patients with disease recurrence 
was  too  small  for  statistical  analysis,  we  analyzed  the  risk 
factors  for  death  or  disease  recurrence.  Lymph  node  meta-
stasis  (p=0.001)  and  the  absence  of  adjuvant  chemotherapy 
(p=0.008)  were  shown  to  be  risk  factors  for  death  or  re-
currence  (Table  4).
DISCUSSION
In  general,  the  role  of  surgery  in  SCLC  is  limited  as 
SCLC is usually treated using chemotherapy or CCRT [3,10]. 
The  important  role  of  chemotherapy  in  SCLC  has  been Surgical Outcome in Small Cell Lung Cancer
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Fig. 3. Comparison of the survival rates in the stage I, II, and III 
groups. The stage I and II groups showed a significantly higher 
survival rate than the stage III group (p=0.001).
Table 4. Risk factor analysis for death or disease recurrence
Variables HR 95%  CI p-value
Age  (＞60  yr)
Gender  (male)
Neoadjuvant  therapy
Tumor  size  (＞3  cm)
T  stage
N  stage
TNM  stage
Tumor  location  (right)
Extent  of  surgery*
Adjuvant  therapy
 0 . 9 7
 0 . 6 0
 0 . 8 9
 0 . 9 3
 1 . 8 7
 5 . 7 2  
11.19
 1 . 0 5
 0 . 7 3
 0 . 1 6
0.90−1.04
0.16−2.25
0.11−7.03
0.66−1.33
0.92−3.80
 2 . 1 7 −15.61
 2 . 8 5 −44.04
0.31−3.48
0.19−2.75
0.04−0.63
0.347
0.445
0.908
0.666
0.085
  0.001*
  0.001*
0.941
0.896
  0.008*
HR=hazard  ratio;  CI=confidence  interval;  TNM=tumor-node-me-
tastasis.
*Comparison  of  the  risk  of  the  extent  of  surgery  by  scoring 
(1=wedge  resection,  segmentectomy,  lobectomy;  2=bilobectomy; 
3=pneumonectomy).
well-established by clinical trials [9,11,12]. Despite the devel-
opment  of  new  chemotherapeutic  agents  for  decades,  SCLC 
r e m a i n s  a  d i s e a s e  w i t h  a  h i g h  m o r t a l i t y  r a t e  a n d  a  l o w  c u r e  
rate,  even  in  limited  stage  groups  [11].  Despite  their  initial 
responses  to  therapy,  most  patients  with  SCLC  develop  local 
recurrence  [12].
There  have  been  some  previous  reports  regarding  the  role 
o f  s u r g e r y  a n d  i t s  o u t c o m e  i n  p a t i e n t s  w i t h  S C L C .  S h a h  e t  
al.  [13]  reported  that  the  five-year  survival  rate  was  43% 
when  treated  with  only  surgery  in  28  patients  with  SCLC. 
Schreiber  et  al.  [14]  indicated  that  the  use  of  surgery,  partic-
ularly  lobectomy,  was  associated  with  favorable  survival 
outcomes.  There  were  other  reports  regarding  the  surgical 
outcome  using  adjuvant  therapies  [1,15-17].  In  these  reports, 
in  the  majority  of  cases,  the  use  of  surgery  as  part  of  multi-
modality therapy had more successful outcomes than those of 
conventional  therapies.  As  seen  in  previous  reports,  current 
CCRT  protocols  have  demonstrated  local  failure  rates  of  ap-
proximately  50%  [18].  Complete  surgical  resection  after  in-
duction  CCRT  has  shown  control  of  local  relapse  in  almost 
100% [19]. This was particularly noticeable in the early stage 
groups (T1-2, N0, M0). In our study, 84% of the stage I and 
II  group  and  13%  of  the  stage  III  group  patients  showed  a 
three-year  survival  rate.  Histologically  mixed  tumors  with 
both SCLC and NSCLC components may fail to meet CCRT 
protocol  requirements  since  there  is  less  sensitivity  of  the 
NSCLC  component  to  chemotherap y .  I t  h a s  b e e n  s h o w n  t h a t  
the  final  histological  findings  for  tumors  that  were  initially 
reported as SCLC indicated that they contained NSCLC com-
ponents in 11% to 25% of patients [20]. In our study, 29.4% 
of  the  patients  had  NSCLC  components  according  to  the 
pathology  review. 
CONCLUSION
O v e r a l l ,  t h e  f i v e - y e a r  p a t i e n t  s u r v i v a l  r a t e  w a s  6 6 . 4 %  i n  
this  study.  Lymph  node  metastasis  and  the  absence  of  ad-
juvant chemotherapy were risk factors for patient death or tu-
mor recurrence. Our study had some limitations. It was a ret-
rospective investigation with only a small number of subjects. 
Despite  these  factors,  according  to  our  study  results,  major 
pulmonary  resection  for  SCLC  was  feasible  in  selected 
patients.  Prospective,  randomized  studies  will  be  needed  to 
determine  the  role  of  surgery  in  early-stage  SCLC.
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